PHARMACYTE BIOTECH INC (PMCB)       2.75  -0.08 (-2.83%)

2.75  -0.08 (-2.83%)

US71715X2036 - Common Stock

PHARMACYTE BIOTECH INC2.75

NASDAQ:PMCB (8/16/2022, 4:20:02 PM)-0.08 (-2.83%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 07-28 2022-07-28/amc Earnings (Next) N/A N/A
Ins Owners N/A Inst Owners 19.68%
Market Cap 57.06M Shares 20.75M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 43.33
IPO 09-11 2003-09-11

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

PMCB Daily chart

Company Profile

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. The company is headquartered in Laguna Hills, California and currently employs 4 full-time employees. The company went IPO on 2003-09-11. The firm is focused on developing and preparing to commercialize cellular therapies for cancer, diabetes and malignant ascites based upon its cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The company is advancing clinical research and development of new cellular-based therapies in oncology and diabetes. The Cell-in-a-Box encapsulation technology enables genetically engineered live human cells to be used to produce various biologically active molecules. Its current generation of product candidates is referred to as CypCaps. The company is developing therapies for pancreatic and other solid cancerous tumours by using genetically engineered live human cells. Its product candidate for the treatment of diabetes consists of encapsulated, genetically modified insulin-producing cells. The firm is also developing therapies for cancer that involve prodrugs based upon certain constituents of the cannabis plant.

Company Info

PHARMACYTE BIOTECH INC

23046 Avenida De La Carlota, Suite 600

Laguna Hills CALIFORNIA

P: 19175952850.0

CEO: Kenneth L. Waggoner

Employees: 4

Website: http://pharmacyte.com/

News

News Imagea day ago - PharmaCyte Biotech, Inc.PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois CapitalNews Image19 days ago - PharmaCyte Biotech, Inc.PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent SolicitationNews Imagea month ago - PharmaCyte Biotech, Inc.PharmaCyte Biotech Commences First Phase of Two-Phase Pig StudyNews Imagea month ago - PharmaCyte Biotech, Inc.PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model StudyNews Imagea month ago - PharmaCyte Biotech, Inc.PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022

PMCB Twits

Here you can normally see the latest stock twits on PMCB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example